SAN DIEGO — Tolebrutinib, a novel Bruton’s tyrosine kinase (BTK) inhibitor that targets neuroinflammation, slowed disability progression by 31% in patients with nonrelapsing secondary progressive multiple […]

SAN DIEGO — New data confirmed the safety and efficacy of AXS-05, a combination of dextromethorphan and bupropion, for the treatment of agitation associated with Alzheimer’s […]

The National Institute for Health and Care Excellence (NICE) has published a draft guideline aimed at standardising rehabilitation services across five chronic neurological conditions. The guidance […]

SAN DIEGO — Transcutaneous peripheral nerve stimulation delivered via a wristband has shown promise in treating essential tremor (ET), a common movement disorder that significantly affects […]

SAN DIEGO — Inebilizumab (Uplizna, Amgen) is safe and effective up to 52 weeks in patients with generalized myasthenia gravis (MG), new research suggested. If approved, the […]

SAN DIEGO — An adjunctive, first-in-class investigational prescription digital therapeutic significantly reduced monthly migraine days (MMDs) in patients with episodic migraine (EM) compared with sham results […]

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a significantly lower risk of dementia and Alzheimer’s disease-related dementia (ADRD), findings from […]

SAN DIEGO — Neuromodulation of the sphenopalatine ganglion (SPG) through transnasal evaporative cooling is a promising nonpharmacologic treatment for acute migraine, results of a randomized controlled […]